Answers are grounded in this paper and cite their sources.
Neutralizing antibodies are key mediators of protection against common viral infections such as SARS-CoV-2, influenza and respiratory syncytial virus (RSV), making them an important target for diagnostic assays assessing immune status and vaccine efficacy. Here we present a novel platform technology that specifically detects SARS-CoV-2 neutralizing antibodies in a simple homogeneous no-wash format as a surrogate virus neutralization test (sVNT). Liposomes loaded with a quenched fluorophore were modified with the angiotensin-converting enzyme 2 (ACE2) receptor, the main receptor for SARS-CoV-2 entry. Virus surrogates based on the receptor binding domain (RBD) of the SARS-CoV-2 spike protein were developed that bind to ACE2-liposomes and contain a trigger moiety, which activates the complement system leading to liposome lysis. Neutralizing antibodies inhibit this binding event and thus prevent the generation of a fluorescent signal. The proof-of-principle was demonstrated using SARS-CoV-2 neutralizing antibodies and pooled human serum, generating IC50 values that can be compared to other assay formats. Testing of 20 SARS-CoV-2 antibody negative sera and 24 sera from individuals with SARS-CoV-2 infection and/or vaccination history, resulted in a specificity of 95%, sensitivity of 96% and a strong correlation (Spearman r = 0.78, Pearson r = 0.77) with antibody titers determined in a pseudovirus neutralization test. The assay platform can be readily adapted to other targets, offering a rapid and straightforward approach to serological immunodiagnostics and in general other competitive assay formats. The simplicity of the assay, the avoidance of washing and immobilization steps renders this format ideally suited for high-throughput screening and point-of-care settings.
No takes yet. Share an insight, caveat, or question.
Hoecherl et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: